[go: up one dir, main page]

EA201491702A1 - Оптимизированные терапевтические агенты для подкожного введения - Google Patents

Оптимизированные терапевтические агенты для подкожного введения

Info

Publication number
EA201491702A1
EA201491702A1 EA201491702A EA201491702A EA201491702A1 EA 201491702 A1 EA201491702 A1 EA 201491702A1 EA 201491702 A EA201491702 A EA 201491702A EA 201491702 A EA201491702 A EA 201491702A EA 201491702 A1 EA201491702 A1 EA 201491702A1
Authority
EA
Eurasian Patent Office
Prior art keywords
therapeutic agents
scrapture
introduction
optimized therapeutic
agent
Prior art date
Application number
EA201491702A
Other languages
English (en)
Other versions
EA033469B1 (ru
Inventor
Вильям Генри
Ричард Вольф-Гаррэвэй
Джон Чарльз Майо
Майкл Джеймс Эрл
Original Assignee
Кантаб Биофармасьютикалз Пэтентс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1206628.8A external-priority patent/GB201206628D0/en
Priority claimed from GBGB1213712.1A external-priority patent/GB201213712D0/en
Priority claimed from GBGB1214985.2A external-priority patent/GB201214985D0/en
Application filed by Кантаб Биофармасьютикалз Пэтентс Лимитед filed Critical Кантаб Биофармасьютикалз Пэтентс Лимитед
Publication of EA201491702A1 publication Critical patent/EA201491702A1/ru
Publication of EA033469B1 publication Critical patent/EA033469B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Предложены способы и дозированные лекарственные формы для подкожного введения, в которых терапевтические агенты модифицированы с увеличением гидрофильности и размеров молекул относительно нативного состояния терапевтического агента, при этом соотношение C:Cниже соотношения C:Cдля указанного агента при его внутривенной доставке.
EA201491702A 2012-04-16 2013-04-16 Подкожное введение конъюгатов факторов крови с полиэтиленгликолем EA033469B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1206628.8A GB201206628D0 (en) 2012-04-16 2012-04-16 Subcutaneous administration of PEGylated blood clotting factors
GBGB1213712.1A GB201213712D0 (en) 2012-08-01 2012-08-01 Modified therapeutic agents
GBGB1214985.2A GB201214985D0 (en) 2012-08-22 2012-08-22 Modified therapeutic agents
PCT/EP2013/057928 WO2013156488A2 (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents

Publications (2)

Publication Number Publication Date
EA201491702A1 true EA201491702A1 (ru) 2015-03-31
EA033469B1 EA033469B1 (ru) 2019-10-31

Family

ID=48190923

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491702A EA033469B1 (ru) 2012-04-16 2013-04-16 Подкожное введение конъюгатов факторов крови с полиэтиленгликолем

Country Status (29)

Country Link
US (2) US20150086524A1 (ru)
EP (1) EP2838566A2 (ru)
JP (3) JP2015512927A (ru)
KR (1) KR102137290B1 (ru)
CN (1) CN104411335A (ru)
AP (1) AP2014008049A0 (ru)
AU (3) AU2013248296A1 (ru)
BR (1) BR112014025737A2 (ru)
CA (1) CA2869993C (ru)
CL (1) CL2014002773A1 (ru)
CO (1) CO7151496A2 (ru)
CR (1) CR20140475A (ru)
EA (1) EA033469B1 (ru)
EC (1) ECSP14023048A (ru)
GB (3) GB201910184D0 (ru)
GE (1) GEP201706716B (ru)
HK (1) HK1200695A1 (ru)
IL (1) IL235129B (ru)
IN (1) IN2014DN08598A (ru)
MD (1) MD20140123A2 (ru)
MX (2) MX2014012512A (ru)
MY (1) MY190257A (ru)
NI (1) NI201400122A (ru)
NZ (1) NZ701205A (ru)
PE (1) PE20150226A1 (ru)
PH (1) PH12014502314B1 (ru)
SG (1) SG11201406492YA (ru)
WO (1) WO2013156488A2 (ru)
ZA (1) ZA201407370B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104073482A (zh) * 2013-12-30 2014-10-01 江苏众红生物工程创药研究院有限公司 聚乙二醇化的组织激肽释放酶及其制备方法和应用
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
FR3034669B1 (fr) * 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
US20180169297A1 (en) * 2015-06-12 2018-06-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Injectable composition of factor vii and fillers
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
CN109998994B (zh) * 2018-02-13 2021-12-07 四川大学 包含药物的柔性脂质体及其制备方法
WO2021165226A1 (en) 2020-02-17 2021-08-26 Biotest Ag Subcutaneous administration of factor viii
EP4138888A1 (en) * 2020-04-23 2023-03-01 Eli Lilly and Company Subcutaneous absorption and bioavailability of antibodies

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CH596313A5 (ru) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
WO1990015628A1 (en) * 1989-06-14 1990-12-27 Cetus Corporation Polymer/antibiotic conjugate
AU5098193A (en) 1992-09-01 1994-03-29 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
DE69332928T2 (de) 1992-09-28 2004-05-06 Research Corp. Technologies, Inc., Tucson Peptidekupplungsreagentien
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
JPH0892294A (ja) * 1994-09-29 1996-04-09 Teijin Ltd ヒト活性化プロテインｃ誘導体
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
JPH08325270A (ja) * 1995-05-31 1996-12-10 Bristol Myers Squibb Co β−ラクタマーゼに対するポリマープロドラッグおよびその使用
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
WO1998032466A1 (en) 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
AU2605099A (en) * 1998-02-25 1999-09-15 Micrologix Biotech, Inc. Indolicidin and cationic peptides conjugated with polymers
ATE428445T1 (de) * 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
EP1280548B1 (en) 2000-05-03 2013-12-11 Novo Nordisk Health Care AG Subcutaneous administration of coagulation factor VII
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
DE60336555D1 (de) * 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
PT1517710E (pt) * 2002-06-21 2011-07-08 Novo Nordisk Healthcare Ag Glicoformas do factor vii peguilado
BRPI0407882B1 (pt) * 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
PT1620118E (pt) * 2003-04-08 2014-10-16 Yeda Res & Dev Fármacos peguilados de modo reversível
US20130137157A1 (en) * 2003-04-09 2013-05-30 Novo Nordisk A/S Glycopegylated factor vii and factor viia
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US20060198819A1 (en) 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
WO2005084679A1 (ja) 2004-03-04 2005-09-15 Eisai R & D Management Co., Ltd. ベンズアミジン誘導体含有組成物及びベンズアミジン誘導体の安定化方法
AU2005260763B2 (en) * 2004-06-30 2011-12-22 Nektar Therapeutics Polymer-factor IX moiety conjugates
WO2006013202A2 (en) 2004-08-02 2006-02-09 Novo Nordisk Health Care Ag Conjugation of fvii
EP1891231A4 (en) 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
EP1937719A4 (en) * 2005-08-19 2010-11-24 Novo Nordisk As FACTOR VII AND GLYCOPEGYLE VIIA FACTOR
BRPI0708832A2 (pt) * 2006-03-31 2011-06-14 Baxter Int construÇço proteinÁcea
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
CA2670618C (en) 2006-12-15 2016-10-04 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
CN101678119B (zh) * 2006-12-27 2014-02-12 尼克塔治疗公司 具有可释放的键合的血管性血友病因子-和因子ⅷ-聚合物轭合物
US20100143326A1 (en) 2007-01-03 2010-06-10 Novo Nordisk Healthcare A/G SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES
WO2008119815A1 (en) * 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
CN101743309B (zh) 2007-04-13 2014-01-29 催化剂生物科学公司 修饰的因子ⅶ多肽及其应用
EP2014299A1 (en) 2007-07-11 2009-01-14 Novo Nordisk A/S Subcutaneous administration of coagulation factor VII
DK2209494T3 (en) 2007-10-09 2016-10-03 Polytherics Ltd New conjugated proteins and peptides
CN103705507A (zh) 2007-10-16 2014-04-09 环状药物公司 凝血因子viia调节剂的制造、组合物和用途
RU2573587C2 (ru) 2008-02-27 2016-01-20 Ново Нордиск А/С Конъюгированные молекулы фактора viii
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
EP2282767A4 (en) * 2008-04-16 2012-07-11 Bayer Healthcare Llc MODIFICATION OF FACTOR IX ORIENTED SITE
RU2496521C2 (ru) * 2008-04-24 2013-10-27 Кантаб Байофармасьютикалз Патентс Лимитед Конъюгаты фактора ix с увеличенным временем полужизни
WO2009141433A1 (en) * 2008-05-23 2009-11-26 Novo Nordisk Health Care Ag Low viscosity compositions comprising a pegylated gla-domain containing protein
EP2326349B1 (en) 2008-07-21 2015-02-25 Polytherics Limited Novel reagents and method for conjugating biological molecules
ES2441941T3 (es) * 2008-10-15 2014-02-07 Baxter Healthcare Sa Pegilación de factores de coagulación sanguínea recombinantes en presencia de anticuerpos enlazados
NZ592688A (en) * 2008-10-17 2012-12-21 Baxter Int Modified blood factors comprising a low degree of water soluble polymer
EP2387413A4 (en) * 2009-01-19 2015-12-23 Bayer Healthcare Llc PROTEIN CONJUGATE WITH AN ENDOPEPTIDASE-SPLICABLE BIOPROTEKTIVES PART
WO2011017055A2 (en) * 2009-07-27 2011-02-10 Baxter International Inc. Blood coagulation protein conjugates
WO2011101242A1 (en) * 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
PL2598172T3 (pl) * 2010-07-30 2019-09-30 Baxalta GmbH Katalizatory nukleofilowe do wiązania oksymowego
WO2012088123A1 (en) * 2010-12-22 2012-06-28 Nektar Therapeutics Polymer-factor vii moiety conjugates

Also Published As

Publication number Publication date
AP2014008049A0 (en) 2014-11-30
JP2015512927A (ja) 2015-04-30
US11351112B2 (en) 2022-06-07
SG11201406492YA (en) 2014-11-27
KR102137290B1 (ko) 2020-07-23
AU2013248296A1 (en) 2014-11-13
CO7151496A2 (es) 2014-12-29
CA2869993A1 (en) 2013-10-24
US20150086524A1 (en) 2015-03-26
AU2018200111A1 (en) 2018-01-25
GB201418864D0 (en) 2014-12-03
CA2869993C (en) 2023-05-23
MD20140123A2 (ru) 2015-04-30
ZA201407370B (en) 2017-09-27
IL235129A0 (en) 2014-12-31
WO2013156488A3 (en) 2014-01-16
WO2013156488A2 (en) 2013-10-24
PH12014502314A1 (en) 2015-01-12
GB2516388A (en) 2015-01-21
MX2014012512A (es) 2015-01-15
EA033469B1 (ru) 2019-10-31
IL235129B (en) 2022-06-01
MX2020014208A (es) 2021-03-09
HK1200695A1 (en) 2015-08-14
PH12014502314B1 (en) 2020-01-31
AU2020200842A1 (en) 2020-02-27
PE20150226A1 (es) 2015-02-14
CN104411335A (zh) 2015-03-11
GB201910190D0 (en) 2019-08-28
CL2014002773A1 (es) 2015-01-16
BR112014025737A2 (pt) 2017-07-04
JP2018024684A (ja) 2018-02-15
IN2014DN08598A (ru) 2015-05-22
EP2838566A2 (en) 2015-02-25
ECSP14023048A (es) 2015-11-30
MY190257A (en) 2022-04-11
KR20140146171A (ko) 2014-12-24
JP6550107B2 (ja) 2019-07-24
NZ701205A (en) 2016-02-26
JP2019131593A (ja) 2019-08-08
GB201910184D0 (en) 2019-08-28
US20180036229A1 (en) 2018-02-08
NI201400122A (es) 2016-12-02
AU2018200111B2 (en) 2019-11-07
GEP201706716B (en) 2017-08-10
CR20140475A (es) 2015-01-23

Similar Documents

Publication Publication Date Title
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
EA201370178A1 (ru) Стабильные составы для парентеральной инъекции пептидных лекарственных средств
EA033373B1 (ru) Композиции на водной основе, предварительно наполненный шприц, их применения и способ доставки гипофукозилированного или нефукозилированного антитела против baffr млекопитающему
EA201590058A1 (ru) Аналоги глюкагона
MX347504B (es) Formulaciones concentradas de proteina y usos de las mismas.
EA201400993A1 (ru) Антитела против рецептора эпидермального фактора роста, активные в определенных условиях, и способы их применения
EA201690618A1 (ru) Ингибиторы тирозинкиназы брутона
EA201170940A1 (ru) Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
BR112014024494A2 (pt) dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
AU2016204185A1 (en) Methods of administering beta7 integrin antagonists
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
EA201590061A1 (ru) Фармацевтическая композиция
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
MX382476B (es) Dispersiones solidas de bendamustina e infusion continua.
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
EA201590521A1 (ru) Инъекционные раковые композиции
UY34154A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel.
UA111785C2 (uk) Композиція для лікування бородавок та спосіб лікування бородавок
EA201500065A1 (ru) Инъецируемый супернасыщенный раствор ацетаминофена для спинального введения
EA201592232A1 (ru) Применение денцихина в получении лекарственного средства для лечения тромбоцитопении
RU2012110137A (ru) Способ лечения инсулинорезистентности
RU2013119140A (ru) Способ лечения вегетососудистой дистонии у детей и подростков
UA79052U (ru) Способ иммунокоррекции при обострениях хронического бронхита у больных с инсулинорезистентностью
UA90816U (ru) Соединение 1,1'-(2''-бром-2''-хлорэтенил)-бис-(6-метилурацил) с потенциальными физиологическими свойствами